Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG2 | P78540 | 15/20 | 0.67 |
| ▸ | ARG1 | P05089 | 14/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15664945 | 0.81 | ARG2 (0.64) | ARG2ARG1CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL21285674 | 0.80 | ARG2 (1.00) | ARG2ARG1 | |
| SCHEMBL893861 | 0.80 | ARG2 (1.00) | ARG2ARG1 | |
| Hydrochloric Acid SCHEMBL894870 | 0.79 | ARG2 (0.97) | ARG2ARG1 | |
| SCHEMBL30169846 | 0.78 | ARG1 (0.60) | ARG2ARG1 | |
| SCHEMBL7094527 | 0.78 | ARG2 (0.60) | ARG2ARG1CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL31042202 | 0.77 | ARG1 (0.59) | ARG2ARG1 | |
| SCHEMBL31042217 | 0.77 | ARG1 (0.59) | ARG2ARG1 | |
| SCHEMBL31042229 | 0.77 | ARG1 (0.59) | ARG2ARG1 | |
| SCHEMBL31042199 | 0.77 | ARG1 (0.59) | ARG2ARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2017-06-29 | — | — | US | disclosed |
| US-9040703-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-12-18 | — | — | US | disclosed |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | ARG2 2/4885ARG1 1/4885CYP2D6 459/4885 |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | ARG2 2/4885ARG1 1/4885CYP2D6 459/4885 |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | ARG2 2/4885ARG1 1/4885CYP2D6 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.